Does the impact of metabolic syndrome on cardiovascular events vary by using different definitions? by unknown
RESEARCH ARTICLE Open Access
Does the impact of metabolic syndrome on
cardiovascular events vary by using
different definitions?
Hossein Khosravi-Boroujeni1, Faruk Ahmed1, Masoumeh Sadeghi2, Hamidreza Roohafza2, Mohammad Talaei3,
Minoo Dianatkhah4, Ali Pourmogaddas4 and Nizal Sarrafzadegan4*
Abstract
Background: Metabolic Syndrome (MetS) is a complex disorder which increases the risk of chronic diseases,
including cardiovascular diseases and diabetes mellitus. As a result of modern lifestyles, the prevalence of MetS
has been rising globally. This study aims to investigate whether overall prevalence of MetS varies when using
different definitions of MetS and to identify the best and most predictive definition of the MetS for cardiovascular
disease (CVD) events over 10 years in a cohort of an Iranian population.
Method: Adults aged ≥ 35 years from urban and rural regions in central Iran were selected at baseline and
followed up for more than 10 years. Data on socio-demographic characteristics, anthropometry, blood pressure
and smoking status were collected at baseline. In addition, various biochemical indices were assessed. MetS was
defined based on five available definitions, and cardiovascular events during 10 years follow up were confirmed
by an expert group. The hazard ratios were calculated by the Cox proportional hazards model.
Results: The highest prevalence of MetS was observed by using AHA-NHBI definition (36.9 %), followed by JIS
definition (31.2 %). On the other hand, EGIR (8.8 %) provided the lowest prevalence. The risk of developing CVD,
irrespective of definitions, was approximately two fold higher in the presence of MetS. After controlling for possible
confounders, AHA-NHBI definition was found to be the best predictor of CVD.
Conclusion: This study demonstrated a great variability in the prevalence of MetS among Iranian adults when
using different definitions of MetS. CVD risk was significantly higher in MetS participants, as well as in participants
with any risk factors of MetS; however, the AHA-NHBI definition was found to be the best predictor of CVD. Thus
protective measures, including lifestyle modifications, plus control of individual risk factors is necessary to prevent
cardiovascular events.
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Background
Metabolic Syndrome (MetS) is a complex disorder with a
collection of related metabolic risk factors which increase
the risk of developing chronic diseases, such as athero-
sclerotic cardiovascular disease (ASCVD) and diabetes
mellitus [1]. MetS is also associated with other disorders
such as fatty liver [2], cholesterol gallstones [3], polycystic
ovary syndrome [4], and sleep apnea [5]. In addition, it
poses a significant risk of higher morbidity, mortality
and financial burden [6]. The prevalence of MetS has
been rising in both developed and developing countries,
probably as a consequence of modern lifestyle and the
overweight/obesity epidemic [7]. Therefore, MetS is
considered a public health, as well as a clinical, prob-
lem. During the past decades, due to major lifestyle
changes and aging population, the prevalence of MetS,
cardiovascular diseases (CVD) and other chronic dis-
eases has been increasing in Iran [8]. Based on a na-
tional study, MetS has been diagnosed in 34.7 to 37.4 %
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of the Iranian population [9]. Moreover, high incidence
rates for almost all CVD and mortality have been re-
ported in the Iranian population [10].
The etiology of MetS has not been clearly defined,
thus the definition of MetS is not based on etiology and
pathology, but on the predictors of CVD as a primary
outcome of MetS. It’s diagnostic criteria have been de-
veloped on the basis of best clustering of interrelated
risk factors of CVD which occur simultaneously and
can predict CVD events [11]. In the past, several expert
groups have attempted to develop practical diagnostic
criteria to characterize individuals who are at high risk
of CVD. They included underlying and metabolic risk
factors, characterized by insulin resistance or impaired
blood glucose, central obesity, dyslipidemia (increase in
triglycerides and decrease in high density lipoprotein
cholesterol (HDL) levels) and hypertension. However,
the suggested criteria varies to some extent and some indi-
viduals might diagnose with one or two definitions but
not with others [12–14].
Because there is no exclusive definition for the diag-
nosis of MetS, its prevalence, incidence and its associ-
ation with an increased risk of cardiovascular diseases
depends on the criteria used [15]. Thus, this study aims
to investigate whether the prevalence of MetS varies
when using different definitions of MetS in an Iranian
population. In addition, it aims to determine the defin-
ition that is the best predictor for CVD events over
10 years in a cohort of an Iranian population.
Methods
Study design
The Isfahan Cohort Study (ICS) is an ongoing, popula-
tion based, longitudinal study of adults aged ≥ 35 years,
from urban and rural regions in central Iran. It is de-
signed to display the incidence of CVD and its risk fac-
tors, and to determine the Iranian risk assessment
values. Participants were selected between January and
September 2001 by multistage random sampling and
were enrolled to represent the age, gender and urban/
rural distribution of their societies. The study details
are presented elsewhere [16]. The study was approved
by the Ethics Committee of the Isfahan Cardiovascular
Research institute (ICRI) a World Health Organization
(WHO) collaborating center and the Griffith University
Ethics Committee.
Measurements
After obtaining the informed written consent of partici-
pants, physical examinations, fasting blood samples, and
anthropometric measurements were carried out. Serum
triglycerides, fasting blood glucose (FBG), and total choles-
terol (TC), were determined using the enzymatic method
[17]. Serum HDL-C was measured after precipitation of
low density lipoprotein (LDL) and very low-density lipo-
protein (VLDL) [18]. The LDL level was calculated by
Friedewald formula [19]. Weight and height were mea-
sured by a calibrated scale and stadiometer with par-
ticipants wearing light clothes and no shoes. Waist
circumference (WC) was measured with non-elastic
measuring tape at or below the costal margin (minimal
waist) without compressing the tissue. Blood pressure
was taken twice at 5 min interval in a sitting position
with a mercury sphygmomanometer with an appropri-
ate cuff for adults. The mean value of the two mea-
surements was calculated and applied.
Metabolic syndrome definitions
Among the available definitions for MetS, this study se-
lected the most widely practiced definitions which were
developed by various international expert groups and or-
ganizations. The MetS was defined according to five def-
initions (Table 1). Based on the WHO definition, insulin
resistance is required for diagnosing MetS, along with
two other risk factors among central obesity, high trigly-
ceride, low HDL or hypertension [12]. The European
Group for Study of Insulin Resistance (EGIR) defined
MetS only for non-diabetic people [20]. The National
Cholesterol Education Program, Third Adult Treatment
Panel (NCEP ATP III) did not emphasise any risk fac-
tors, but the presence of any 3 of the 5 risk factors
would qualify a person for MetS [14]. Based on the
International Diabetes Foundation (IDF), abdominal
obesity is a requirement in MetS definition, and having
central obesity plus any other two risk factors are re-
quired for the diagnosis of MetS [13]. This definition
insists on easy-to-use measures in clinical practice, and
moreover, emphasises ethnic differences in recognising
the cut-off point of abdominal obesity [21]. The American
Heart Association (AHA) and the National Heart, Lung,
and Blood Institute (NHLBI) accepted the ATP III def-
inition, but reduced the threshold for impaired glucose
tolerance (IFG) from 110 to 100 mg/dl [22]. A harmo-
nized definition of MetS (a Joint Interim Statement
(JIS)) formulated by several organizations including
IDF, NHLBI, AHA, the World Heart Federation, the
International Atherosclerosis Society and the International
Association for the Study of Obesity attempted to develop
a unified criteria for defining MetS. They agreed that a
single cut-off point for WC is not suitable and should not
be a required component. Furthermore, any 3 out of 5
components are adequate for MetS diagnosis [11].
Follow up
With the purpose of verifying CVD events, the follow-
up of participants was conducted using telephone call
interviews and home visits when required, every two
years. The participants were asked about their hospital
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Table 1 Different definitions of metabolic syndrome
WHO EGIR NCEP ATP III AHA IDF JIS
Definitions insulin resistance together
with two or more of the
following:
Insulin resistance or impaired
fasting glucose (IFG) plus two
of the following:
Three or more of the
following five risk factors:
Three or more of the
following five risk factors:
Central obesity plus 2
other features
Three or more of the
following five risk factors:
Fasting plasma
glucose
__ ≥ 6.1 mmol/l (110 mg/dl)
but non-diabetic
≥ 6.1 mmol/l (110 mg/dl) ≥ 5.6 mmol/l (100 mg/dl) ≥ 5.6 mmol/l (100 mg/dl)














Ethnic cut point for waist
circumferencea
Women: waist-hip ratio > 0.85




circumference > 88 cm
Women: waist
circumference > 88 cm
Women: waist circumference
≥ 80 cma or BMI > 30 kg/m2
Blood pressure ≥ 140/90 mmHg ≥ 140/90 mmHg or
treatment
≥ 130/85 mmHg ≥130/85 mmHg ≥ 130/85 mmHg or
treatment
≥ 130/85 mmHg
Triglycerides ≥ 1.7 mmol/l (150 mg/dl) > 2.0 mmol/l (178 mg/dl) ≥1.7 mmol/l (150 mg/dl) or
treatment
≥1.7 mmol/l (150 mg/dl)
or treatment
≥1.7 mmol/l (150 mg/dl)
or treatment




Men: < 0.9 mmol/l (35 mg/dl) < 1.0 mmol/l (39 mg/dl)
or treatment
Men: < 1.03 mmol/l (40 mg/
dl)




Men: < 1.03 mmol/l
(40 mg/dl)
Women: < 1.0 mmol/l
(39 mg/ dl)
Women: < 1.29 mmol/l
(50 mg/ dl)
Women: < 1.29 mmol/l
(50 mg/dl)
Women: <1.3 mmol/l
(40 mg/dl) or treatment
Women:
< 1.29 mmol/l (50 mg/dl)












admissions or any cardiac or neurological symptoms that
led to visiting a physician. In 2007 and 2013, interviews,
physical examinations and laboratory tests were repeated
for all participants. The measurement methods were simi-
lar to the 2001 survey. Acute myocardial infarction (AMI),
unstable angina (UA), and sudden cardiac death were con-
sidered as the indicators of ischemic heart disease. A panel
of three cardiologists and one neurologist, unaware of the
data related to risk factors, examined all the documents to
confirm the CVD cases. For the purpose of this study, the
data on CVD event were recorded up to the 2013 survey.
Statistical methods
The prevalence of MetS was calculated by using different
definitions in the total samples and also by considering
sex, age category, region, education level, and occupation
using SPSS crosstab. For univariate analysis, the data were
compared between groups by the Student t-test or chi-
squared analysis. Based on our variables (the follow up
duration and the CVD event), the Cox proportional haz-
ards model was chosen as the best multivariate approach
for analysing survival time data to investigate the associ-
ation of different definitions of MetS and its components
with cardiovascular events. In the first model, the analysis
was conducted using a crude model, and in the second
model, age, sex, smoking status and physical activity were
adjusted to remove the effects of covariates. For all ana-
lyses, statistical significance was considered at a level of
0.05. All data were analysed by using Statistical Package
for the Social Sciences (IBM SPSS Version 22).
Results
Overall, 3336 females and 3168 males participated in the
first phase of the ICS. When compared between various
definitions of MetS, the highest prevalence was observed
using the AHA-NHBI definition (36.9 %), followed by
JIS (31.2 %) and ATP III (30.0 %). On the other hand
WHO (13.3 %) and EGIR (8.8 %) provided a much lower
prevalence (Table 2). Considering all definitions, the
overall prevalence of MetS was higher in females than in
males. Using WHO and EGIR definitions, the prevalence
of MetS rose with increasing age, while it increased only
until 65–75y using all other definitions.
Table 3 shows the presence of CVD events based on
the development of MetS using different definitions. Ir-
respective of the definitions used, MetS was signifi-
cantly associated with CVD events. Higher values of
CVD risk factors (e.g. age, cholesterol, blood glucose
and smoking) were also observed in individuals with
CVD events. However, HDL-C was an exception in that
there was no significant difference in the levels between
the CVD events groups.
The risk of developing CVD, considering all defini-
tions, was approximately two fold higher in the presence
of MetS (Table 4). As shown in the crude model, the
MetS using the WHO definition predicted the highest
risk for CVD followed by the JIS definition (HR: 2.41,
95 % CI: 2.05–2.83 and HR: 2.14, 95 % CI: 1.86–2.46 re-
spectively). After controlling for possible confounders
including age, sex, smoking status and physical activity,
the risk of CVD decreased slightly and using the AHA-
NHBI definition was found to be a better predictor than
using other definitions (HR: 1.93, 95 % CI: 1.66–2.25).
When examining the risk of CVD events for each of the
abnormal components of MetS, the risk of CVD occur-
rence was also significantly higher. Among the compo-
nents, glucose abnormality was found to be a higher
predictor of CVD events (HR: 1.83, 95 % CI: 1.56–2.15)
than the other components.
Discussion
The present study demonstrated that the prevalence of
MetS among Iranian adults varies widely when different
definitions are used. Using the WHO and EGIR defini-
tions resulted in a much lower prevalence of MetS when
compared with other definitions. Regardless of the defi-
nitions, this study also revealed that diagnosing MetS
can help identify individuals who are at a higher risk of
CVD and can also predict long term CVD events. The
AHA-NHBI definition was found to be the best predictor
of CVD followed by the WHO and ATPIII definitions;
nevertheless, the hazard risk ratios for all definitions were
very close.
Researchers have found that multiple endogenous ori-
gin risk factors of CVD may accumulate in one person
[23]. Thus, MetS has been defined by expert groups as a
functional and simple indicator of the risk of CVD, al-
though the predicted risk depends on which definition
of MetS is used [23]. Some definitions have emphasised
insulin resistance as an essential component for the
Table 2 Prevalence of metabolic syndrome by sex and age
groups based on having MetS using different definitions
MetS definition
WHO EGIR ATPIII AHA-NHBI IDFa JIS
Total 13.3 % 8.8 % 30.0 % 36.9 % 28.0 % 31.2 %
Sex
Male 10.6 % 6.9 % 20.7 % 21.4 % 25.5 % 29.1 %
Female 15.9 % 10.7 % 38.8 % 51.7 % 30.2 % 33.2 %
Age Categories
35–45 7.6 % 5.8 % 19.9 % 28.4 % 19.0 % 21.2 %
45–55 13.1 % 8.5 % 32.7 % 40.6 % 31.4 % 34.2 %
55–65 19.8 % 12.7 % 40.1 % 47.4 % 37.0 % 42.2 %
65–75 21.3 % 13.0 % 43.4 % 46.9 % 37.9 % 42.3 %
> 75 21.9 % 14.4 % 30.5 % 33.3 % 27.8 % 33.7 %
aWaist Circumference ≥ 95 for both sexes
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diagnosis of MetS. For instance, according to the WHO
definition, without insulin resistance, individuals would
not have MetS, even though they have all other criteria
[12]. Insulin resistance influences hyperglycemia and
diabetes mellitus [24], and increases lipolysis of stored
lipids and free fatty acids [25]. Furthermore, it can lead
to vasoconstriction and sodium retention which ultim-
ately cause hypertension [26]. Later, abdominal obesity
was detected to be strongly associated with insulin resist-
ance [27], impaired glucose tolerance (IGT) [28], hyper-
tension [29], hyperlipidemia [30] and increased risk of
coronary heart disease [31]. Abdominal obesity is meta-
bolically active and releases bioactive products such as free
fatty acids [32], inflammatory cytokines and adipokines
[33]. Thus, abdominal obesity is implicated as a MetS risk
factor, and consequently IDF has considered this kind of
obesity to be an essential determinant of the MetS [27].
Surprisingly, it was confirmed that individuals having
inherent insulin resistance, such as individuals with
South Asian ethnicity, can develop insulin resistance and
MetS without an excessive degree of obesity, and even
with a WC below the cut off points [34]. In Asian popu-
lations the NCEP and ATP III definitions underesti-
mated the population at risk [35]. Due to the ethnic
differences, there has been a proposal for using modified
cut-off points for defining central obesity as a risk factor
for MetS [13]. In the current study, the Iranian National
Committee of Obesity cut-off point for WC (≥ 90 cm for
Table 3 Present of cardiovascular events based on different definition of metabolic syndrome
Cardiovascular event
No Yes P
Presence of MetS by different definitions MetS (N) N (%) N (%)
WHO definition Yes (766) 568 (11.8) 198 (25.5) < 0.001
No (4818) 4241 (88.2) 577 (74.5)
EGIR definition Yes (507) 386 (8.0) 121 (15.6) < 0.001
No (5077) 4423 (92.0) 654 (84.4)
ATPIII definition Yes (1701) 1337 (27.8) 364 (47.0) < 0.001
No (3883) 3472 (72.2) 411 (53.0)
AHA-NHBI definition Yes (2093) 1681 (35.0) 412 (53.2) < 0.001
No (3491) 3128 (65.0) 363 (46.8)
IDFa definition Yes (1595) 1266 (26.3) 329 (42.5) < 0.001
No (3989) 3543 (73.7) 446 (57.5)
JIS definition Yes (1773) 1397 (29.0) 376 (48.5) < 0.001
No (3811) 3412 (71.0) 399 (51.5)
Cardiovascular risk factors
Age (years) 49.8 ± 11.3 58.0 ± 11.6 < 0.001
FBS (mg/dl) 87.0 ± 29.9 101.1 ± 48.5 < 0.001
Total Cholesterol (mg/dl) 212.2 ± 51.5 228.8 ± 55.8 < 0.001
HDL-C (mg/dl) 46.9 ± 10.4 47.0 ± 10.6 0.87
LDL-C (mg/dl) 127.6 ± 42.9 138.4 ± 46.3 < 0.001
Triglyceride (mg/dl) 188.2 ± 101.7 217.4 ± 114.5 < 0.001
Waist circumference (cm) 94.4 ± 12.2 97.4 ± 12.4 < 0.001
BMI 26.6 ± 4.4 27.2 ± 4.7 < 0.001
Systolic BP (mmHg) 120.1 ± 20.0 133.5 ± 24.2 < 0.001
Diastolic BP (mmHg) 77.7 ± 11.2 83.1 ± 12.8 < 0.001
Daily Physical Activity (Mets/h 882.4 ± 544.9 755.1 ± 562.9 < 0.001
Smoking < 0.05
Current smoker 769 (16.0) 139 (18.0)
Past smoker 270 (5.6) 64 (8.3)
Never smoker 3763 (78.4) 570 (73.7)
Data presented as number (percent) or mean ± Standard deviation
aWaist Circumference ≥ 95 for both sexes
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both genders) was used to determine the risk for CVD
[36]. Further, it was suggested that there should not be
any compulsory components [11].
Previous studies among different population groups
in Iran have shown varied prevalence of MetS based on
different definitions. However, the patterns of MetS
prevalence, using different definitions [9, 37], were very
similar to those observed in our study. For instance, in
Zabetian et al’s study [37], the prevalence of MetS was
32.1, 33.2 and 18.4 % based on the IDF, ATP III, and
WHO definitions respectively. In Delavari et al’s study
[9] its prevalence was 37.4, 34.7 and 41.6 % based on
the IDF, ATP III, and AHA/NHLBI criteria respectively.
Other studies have also reported that the prevalence of
MetS was approximately 30 % in Iranian adults by the
ATP III definition [38, 39]. It is likely that using differ-
ent population criteria, including different age categor-
ies, gender ratios, living areas and physical activity
levels, might have influenced the reported prevalence of
MetS among studies in Iran. Further, the patterns of
MetS prevalence in other countries, using different def-
initions of MetS, have also reported similar variations.
An earlier study among Australians reported that one
in three was identified with MetS by the IDF definition,
while one in five was identified with MstS by using the
WHO and ATPIII definitions and it was slightly less
when the EGIR definition was used [40].
Previous studies have shown that individuals with
MetS were at higher risk of CVD development in the
near future (approximately 10 years) even after consider-
ing the confounding effects of other major risk factors
such as age, sex, smoking, and hypercholesterolemia
[41–46] which is in line with our results. Although the
current study found that the WHO and IDF criteria for
MetS was related to a high risk for CVD events (HR:
1.92 and 1.65 respectively), their requirements (insulin
resistance or abdominal obesity) make it difficult to
diagnose high risk individuals without insulin resistance
or abdominal obesity. There was also a slight difference
in CVD risk between the JIS, AHA-NHBI and ATP III
definitions, which was principally because of the vari-
ation in their definition and threshold for impaired fast-
ing glucose and WC. The definition which has higher
sensitivity and identified a higher number of individuals
who are at risk of CVD is the best. In the current study,
the AHA-NHBI definition was associated with higher
prevalence of MetS, as well as higher CVD risk. Thus,
AHA-NHBI definition can be nominated as the best in-
dicator to identify MetS for this study population. On
the other hand, as the only difference between the AHA
and JIS definitions is the WC threshold, our results
showed that the suggested cut-off point for WC in the
Iranian population may not be satisfactory and there is a
need for redefining the WC cut-off point for the best es-
timation of CVD risk in this population.
The present study also found a significant association
between the risk of CVD and MetS components. The
associated risk was higher for glucose intolerance or
diabetes (HR: 1.83, 95 % CI: 1.56–2.15) than any other
MetS components, which is in line with previous re-
search [47]. In addition, when the risk of CVD was ex-
amined based on the presence of MetS risk factors,
more MetS components were associated with a higher
risk of cardiovascular events. The risk of CVD for indi-
viduals having four and five components of MetS was
2.98 and 6.06 respectively (data not shown). Thus, it
may also be necessary to examine the number of com-
ponents in MetS individuals to identify the individuals
Table 4 Hazard Ratio of CVD occurrence based on different definitions of metabolic syndrome and its components
Metabolic syndrome definitions Crude HR (95 % CI) P-Value Adjusted HRb (95 % CI) P-Value
WHO 2.41 (2.05–2.83) < 0.001 1.92 (1.62–2.26) < 0.001
EGIR 2.03 (1.67–2.47) < 0.001 1.66 (1.37–2.03) < 0.001
ATPIII 2.12 (1.84–2.44) < 0.001 1.87 (1.61–2.16) < 0.001
AHA-NHBI 1.98 (1.72–2.28) < 0.001 1.93 (1.66–2.25) < 0.001
IDFa 1.93 (1.67–2.23) < 0.001 1.65 (1.43–1.91) < 0.001
JIS 2.14 (1.86–2.46) < 0.001 1.80 (1.56–2.08) < 0.001
Metabolic syndrome components
Obesity 1.51 (1.31–1.75) < 0.001 1.44 (1.24–1.67) < 0.001
High triglyceride 1.67 (1.43–1.95) < 0.001 1.60 (1.37–1.87) < 0.001
High LDL-C 1.49 (1.28–1.74) < 0.001 1.30 (1.11–1.52) < 0.01
Low HDL-C 1.07 (0.91–1.25) 0.404 1.19 (1.01–1.39) < 0.05
Hypertension 2.51 (2.18–2.89) < 0.001 1.79 (1.53–2.08) < 0.001
Glucose intolerance/ Diabetes 2.21 (1.88–2.59) < 0.001 1.83 (1.56–2.15) < 0.001
aWaist Circumference ≥ 95 for both sexes
bAdjusted Model for age, sex, smoking status and physical activity
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at higher risk of CVD. Nevertheless, other risk factors
of MetS including family history of diseases, age, gen-
der, smoking, LDL or total cholesterol levels should be
considered for CVD risk factors [48].
This study has some limitations. First, insulin resist-
ance was not assessed directly, but instead, oral glucose
tolerance test was used to estimate insulin sensitivity.
Nevertheless, it is accepted that this measurement can
be linked with insulin resistance [49]. Further, cohort
studies are inherently limited for loss-to-follow up par-
ticipants. However, the characteristics of individuals did
not differ to a great extent as a result of drop-outs. On
the other hand, the strength of this study is that to the
best of our knowledge, it is the first study that has
looked at the HR of CVD events occurrence based on
MetS components and different definitions of MetS in a
longitudinal study, in urban and rural areas in Eastern
Mediterranean countries. Further, this study draws at-
tention to the importance of having a national cut-off
point for WC for the Iranian population, which could
diagnose the individuals at higher risk of CVD. The
present study also emphasises the importance of individ-
ual components of MetS for prediction of CVD risk.
Conclusion
In conclusion, this representative sample of Iranian adults
revealed a varied prevalence of MetS when using differ-
ence definitions of MetS. Further, follow-up of participants
for more than 10 years showed that CVD risk was signifi-
cantly higher in MetS participants, irrespective of the used
definitions, as well as in participants with any risk factors
of MetS. Overall, the AHA-NHBI and JIS definitions were
better indicators because they were able to capture more
individuals with MetS who were not identified by the
EGIR and WHO definitions and were also at higher risk
of CVD. Finally, the findings of this study emphasise the
need for using the best possible population specific indica-
tors for identifying MetS individuals. In addition, there is
an urgent need for the development and implementation
of appropriate protective measures, including lifestyle
modifications, to improve all the MetS components. Con-
trol of individual components to prevent cardiovascular
events is also necessary.
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